About
About Bioheng
History
Science & Products
Pipelines
Technology Platforms
Publications
News
Event Highlights
Contact
Investor Relations&BD
03
2021-03
Bioheng Raised $80 Million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies
NANJING, China, March 24, 2021 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company聽 dedicated聽on developing novel cellular immunotherapy for cancer, today announced that it had secured聽$80 million聽in Series B Financing. The Series B was co-led by GL Ventures, the venture capital unit of Hillhouse Capital, Decheng Capital and Octagon Capital, with the participation of BlueRun Ventures聽China and Shenzhen Capital Group Company.
11
2020-11
Bioheng Announced Oral Presentation of Its Preliminary Results of CRISPR-Engineered Allogeneic CAR-T for r/r B-ALL Treatment at 2020 ASH Meeting
NANJING, China, Nov. 10, 2020聽-- Bioheng Biotech Co., Ltd, a clinical-stage biotech company focused on developing novel cellular immunotherapy to treat cancer, today announced an oral presentation at 62th The data will be presented regarding the pre-clinical development, manufacturing, and IIT clinical results of the company鈥檚 lead product, CTA101, a CRISPR-Cas9-engineered off-the-shelf CD19/CD22 dual-targeted CAR T cell product, in patients with relapsed / refractory B-cell acute Lymphoblastic Leukemia.
Contact Us
Consult Now